YANTAI, China, Aug. 19, 2025 /PRNewswire/ --?RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th,?Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sj?gren's syndr...
YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple ad...
YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025,?RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰愛?) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of Myasthenia Gravi...
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV...
YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27,?RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept?has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of adult patients with anti-acetylcholine recepto...
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 愛地希? ), the first domestically approved antibody-drug conjugate (ADC...
YANTAI, China, April 9, 2025 /PRNewswire/ --?On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰愛?) in patients with generalized myasthenia?gravis (gMG) were presented during the ...
YANTAI, China, Feb. 15, 2025 /PRNewswire/ -- On the morning of February 14, 2025 (UTC-8), at the ongoing 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held inSan Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital delivered the lates...
YANTAI, China, Jan. 8, 2025 /PRNewswire/ --?On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase1b/2 clinical trial on Disitamab Vedotin (DV)?(developed by Remegen Co., Ltd) combined with Toripalimab in ...
YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...
YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...
YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ? for the treatment of generalized myasthenia gravis (gMG) has been officially...
YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ?("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept h...
YANTAI,?China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ?("RemeGen" or "the Company") (9995.HK,?SHA:?688331), a commercial-stage biotechnology company,?showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annu...
YANTAI, China, June 4, 2024 /PRNewswire/ --?RemeGen Co., Ltd. ?("RemeGen" or "the Company") (9995.HK,?SHA:?688331), a commercial-stage biotechnology company,?presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...
YANTAI, China, May 21, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ?("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant progress of Telitacicept (RC18), that two Phase III clinical trials inChina for the t...
The biotech company continues to offer hope to systemic lupus erythematosus?( SLE) patients globally by sharing the latest developments of its proprietary novel fusion protein drug Telitacicept YANTAI,?China, May 10, 2024 /PRNewswire/ --?RemeGen Co. Ltd. ?("RemeGen" or "t...
YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently?for its inno...
YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab ...